Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Parissa Keshavarzian"'
Autor:
Hatim Husain, Scott M. Lippman, Fernando J. Lopez-Diaz, Brian D. Woodward, Parissa Keshavarzian, John Paul Shen, Ajaz Bulbul, Ayesha Murtuza
EGFR-activating mutations are observed in approximately 15% to 20% of patients with non–small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative example of the successes in targeting oncogene addiction in cancer and the role
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5880488cbc28057784b3cc4ee360618d
https://doi.org/10.1158/0008-5472.c.6511314.v1
https://doi.org/10.1158/0008-5472.c.6511314.v1
Autor:
Hatim Husain, Scott M. Lippman, Fernando J. Lopez-Diaz, Brian D. Woodward, Parissa Keshavarzian, John Paul Shen, Ajaz Bulbul, Ayesha Murtuza
Clinical Outcomes with Various Third Generation EGFR Inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be7527af240419c04540e2f8d58e74ed
https://doi.org/10.1158/0008-5472.22422693.v1
https://doi.org/10.1158/0008-5472.22422693.v1
Autor:
Hatim Husain, Victor E. Velculescu, Robert B. Scharpf, Valsamo Anagnostou, Elizabeth Weihe, Vilmos Adleff, Parissa Keshavarzian, Daniel C. Bruhm, Christopher D. Gocke, Doreen N. Palsgrove, Stephen Cristiano, Jamie E. Medina, Jacob Fiksel, Julie R. Brahmer, Kristen A. Marrone, Jarushka Naidoo, Patrick M. Forde, Brian D. Woodward, Alessandro Leal, Jillian Phallen
The supplementary tables for "Early noninvasive detection of response to targeted therapy in non-small cell lung cancer" report clinical characteristics of patients analyzed (1), serial timepoints analyzed (2), genes analyzed (3), a summary of genomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ba01d05eb1651648d31488dbb700b8b
https://doi.org/10.1158/0008-5472.22423020.v1
https://doi.org/10.1158/0008-5472.22423020.v1
Autor:
Hatim Husain, Scott M. Lippman, Fernando J. Lopez-Diaz, Brian D. Woodward, Parissa Keshavarzian, John Paul Shen, Ajaz Bulbul, Ayesha Murtuza
Chemical Structures of Third Generation Anti-EGFR Compounds
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fde5c4078b1738b7f01e4a9f530ae4f
https://doi.org/10.1158/0008-5472.22422696
https://doi.org/10.1158/0008-5472.22422696
Autor:
Hatim Husain, Scott M. Lippman, Fernando J. Lopez-Diaz, Brian D. Woodward, Parissa Keshavarzian, John Paul Shen, Ajaz Bulbul, Ayesha Murtuza
EGFR Receptor Signaling and Bypass Pathways
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::543b85e8a4e4afc98b305d22f682a0bd
https://doi.org/10.1158/0008-5472.22422699
https://doi.org/10.1158/0008-5472.22422699
Autor:
Hatim Husain, Victor E. Velculescu, Robert B. Scharpf, Valsamo Anagnostou, Elizabeth Weihe, Vilmos Adleff, Parissa Keshavarzian, Daniel C. Bruhm, Christopher D. Gocke, Doreen N. Palsgrove, Stephen Cristiano, Jamie E. Medina, Jacob Fiksel, Julie R. Brahmer, Kristen A. Marrone, Jarushka Naidoo, Patrick M. Forde, Brian D. Woodward, Alessandro Leal, Jillian Phallen
The supplementary figures for "Early noninvasive detection of response to targeted therapy in non-small cell lung cancer" depict dynamic changes of ctDNA during therapy (S1), copy number changes identified in cfDNA from analyses of whole-genome data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b6817dc7ca991b8fea9af1673d31b89
https://doi.org/10.1158/0008-5472.22423023
https://doi.org/10.1158/0008-5472.22423023
Autor:
Hatim Husain, Victor E. Velculescu, Robert B. Scharpf, Valsamo Anagnostou, Elizabeth Weihe, Vilmos Adleff, Parissa Keshavarzian, Daniel C. Bruhm, Christopher D. Gocke, Doreen N. Palsgrove, Stephen Cristiano, Jamie E. Medina, Jacob Fiksel, Julie R. Brahmer, Kristen A. Marrone, Jarushka Naidoo, Patrick M. Forde, Brian D. Woodward, Alessandro Leal, Jillian Phallen
With the advent of precision oncology, there is an urgent need to develop improved methods for rapidly detecting responses to targeted therapies. Here, we have developed an ultrasensitive measure of cell-free tumor load using targeted and whole-genom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d54fa3cd9918bcb36f5fd2b1ef4222c2
https://doi.org/10.1158/0008-5472.c.6511401.v1
https://doi.org/10.1158/0008-5472.c.6511401.v1
Autor:
Jarushka Naidoo, Daniel C. Bruhm, Jillian Phallen, Stephen Cristiano, Parissa Keshavarzian, Doreen N. Palsgrove, Brian Woodward, Kristen A. Marrone, Victor E. Velculescu, Vilmos Adleff, Elizabeth Weihe, Patrick M. Forde, Jamie E. Medina, Christopher D. Gocke, Alessandro Leal, Robert B. Scharpf, Hatim Husain, Jacob Fiksel, Valsamo Anagnostou, Julie R. Brahmer
Publikováno v:
Cancer research, vol 79, iss 6
With the advent of precision oncology, there is an urgent need to develop improved methods for rapidly detecting responses to targeted therapies. Here, we have developed an ultrasensitive measure of cell-free tumor load using targeted and whole-genom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c46d5607d5910acdda1ac70747f7bd19
https://doi.org/10.1158/0008-5472.can-18-1082
https://doi.org/10.1158/0008-5472.can-18-1082
Autor:
Hatim Husain, John Paul Shen, Scott M. Lippman, Brian Woodward, Fernando J. Lopez-Diaz, Parissa Keshavarzian, Ayesha Murtuza, Ajaz Bulbul
Publikováno v:
Cancer research. 79(4)
EGFR-activating mutations are observed in approximately 15% to 20% of patients with non–small cell lung cancer. Tyrosine kinase inhibitors have provided an illustrative example of the successes in targeting oncogene addiction in cancer and the role
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1d45c37de92c7d407833e7322713163
https://pubmed.ncbi.nlm.nih.gov/30718357
https://pubmed.ncbi.nlm.nih.gov/30718357
Autor:
Jacob Fiksel, Valsamo Anagnostou, Doreen N. Palsgrove, Patrick M. Forde, Julie R. Brahmer, Kristen A. Marrone, Hatim Husain, Robert B. Scharpf, Parissa Keshavarzian, Brian Woodward, Vilmos Adleff, Elizabeth Weihe, Jillian Phallen, Jarushka Naidoo, Daniel C. Bruhm, Stephen Cristiano, Victor E. Velculescu, Alessandro Leal
Publikováno v:
Cancer Research. 78:4596-4596
There is an unmet need for improved methods of rapidly identifying responses to targeted therapies. Liquid biopsy approaches have potential as early biomarkers of response based on noninvasive, real-time monitoring of disease burden. We have used the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd7245443318fbc6f414da00e7d6dd00
https://doi.org/10.1158/1538-7445.am2018-4596
https://doi.org/10.1158/1538-7445.am2018-4596